GlobeNewswire

Elastic Acquires SaaS Site Search Leader Swiftype

Dela

Swiftype's Site Search and Enterprise Search products further extend Elastic's vision to offer tailored solutions on top of the Elastic Stack

MOUNTAIN VIEW, Calif. and AMSTERDAM, The Netherlands, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Elastic, the company behind Elasticsearch, and the Elastic Stack, the most widely-used collection of open source products for solving mission-critical use cases like search, logging, and analytics, today announced that it has acquired Swiftype, a San Francisco-based startup founded in 2012 and backed by Y Combinator and New Enterprise Associates (NEA). Swiftype is the creator of the popular SaaS-based Site Search and the recently introduced Enterprise Search products.

Swiftype is an early adopter of Elasticsearch, using Elasticsearch to index and store searchable content and power the search experience for its Site Search product. Used by more than 900 organizations including Asana, AT&T, Dr. Pepper, Engadget, Hubspot, Marketo, Shopify, SurveyMonkey, and TechCrunch, Site Search offers users the ability to create customized search experiences; a user interface to configure advanced features, such as relevance, autocomplete, faceted search, and custom result ranking; and real-time analytics, reports, and dashboards. Effective immediately, Swiftype's Site Search product will be offered with a new introductory subscription plan starting at $79/month that allows customers to grow at their own pace. In addition, Site Search provides a straightforward migration path for Google Site Search (GSS) customers.

Released earlier this year, Swiftype's Enterprise Search product helps organizations manage content across disparate data sources and seamlessly connect to cloud-based applications like Atlassian, Box, Dropbox, Github, Google Apps, Microsoft Outlook, Salesforce, Slack, Zendesk, and more. Effectively immediately, Enterprise Search will be moved to beta and available for trial upon request. The combined Elastic and Swiftype engineering teams will integrate more capabilities of the Elastic Stack and X-Pack into Enterprise Search and will make it available as both as a hosted service and on-premise solution.

"We've long invested in Elasticsearch to help power the Swiftype platform, given its superior technology for building real-time and scalable search solutions," said Matt Riley, Swiftype Co-Founder and CEO. "Joining forces with the Elastic team and merging our collective best-in-class solutions will drive success for customers, making way for natural opportunities for new and improved products and solutions."

"Swiftype has built an amazing company and a rich set of SaaS products leveraging the power of Elasticsearch as a generic search engine," said Shay Banon, Elastic Founder and CEO. "By joining forces with Swiftype, our customers will be able to address their simple website or application search needs, and in the future, more complex enterprise search use cases with a highly tailored and curated SaaS or on-premise experience."

Learn More

About Elastic
Elastic builds software to make data usable in real time and at scale for search, logging, security, and analytics use cases. Founded in 2012, the company develops the open source Elastic Stack (Elasticsearch, Kibana, Beats, and Logstash), X-Pack (commercial features), and Elastic Cloud (a hosted offering). To date, there have been more than 150 million cumulative downloads. Backed by Benchmark Capital, Index Ventures, and NEA with more than $100 million in funding, Elastic has a distributed workforce with more than 600 employees in 30 countries. Learn more at elastic.co

Elastic Media Contacts:
AMER
Michael Lindenberger
Reidy Communications for Elastic
michael@reidycommunications.com 
+1-415-531-1449

EMEA
Rory MacDonald
Age of Peers Ltd for Elastic
rory@ageofpeers.com 
+44 (0)7899 965232




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Elastic via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum